Search | Clinical Trials Finder

Conditions: Neuroendocrine Tumors
Interventions: Telotristat (Low-Dose), Telotristat (High-Dose); Drug
Lead sponsor: Lowell Anthony, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions: Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 171
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more

Conditions: Meningioma
Interventions: Lutathera; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Interventions: Lutetium [177Lu] oxodotreotide/dotatate; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 3
States / cities: Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Neuroendocrine Tumors
Interventions: Cabozantinib, Lu-177; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glioblastoma
Interventions: [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more

Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Interventions: Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Interventions: 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT); Drug · Procedure
Lead sponsor: Sue O'Dorisio; Other
Eligibility: 1 Year to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions: LUTATHERA® (Lutetium Lu 177 dotatate); Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 4
States / cities: Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Conditions: Neuroendocrine Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more

Conditions: Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions: Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Gallium Ga 68-DOTATATE, Positron Emission Tomography, Questionnaire Administration; Radiation · Drug · Procedure + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Intracranial Meningioma
Interventions: [177Lu]Lu-DOTATATE, Standard of Care treatments; Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Irvine, California • La Jolla, California • New Haven, Connecticut + 12 more

Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 4,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Neuroendocrine Tumors
Interventions: 131-I MIBG and 111-In pentetreotide, 131-I MIBG and In-111 DOTATATE; Other
Lead sponsor: David Bushnell; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Interventions: Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Interventions: cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT); Procedure · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer, Advanced Cancer
Interventions: Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Interventions: Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Yttrium-90 Microsphere Radioembolization; Procedure · Biological · Device
Lead sponsor: Nicholas Fidelman, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions: Lutathera, Azedra; Drug
Lead sponsor: David Bushnell; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
Interventions: Lutetium Lu 177 dotatate therapy; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Telotristat With Lutathera in Neuroendocrine Tumors

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry